Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Les Laboratoires Servier is managing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners and 4 distinct art units. The use of 5 distinct examiners for 5 pending office actions shows a high degree of diversification in the review process across the 4 distinct art units.
CHENG, KAREN is the busiest examiner, holding 1 busiest examiner pending action. Because the total pending office actions is 5, the workload is distributed among the 5 distinct examiners. This distribution suggests that no examiner dominates the current prosecution pipeline, requiring a strategy that addresses 4 distinct art units and multiple examiner preferences. Managing the 5 pending office actions requires coordination to ensure consistent claim interpretations across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHENG, KAREN | 1 | 76.3% | +26.7% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
| SKOKO III, JOHN JOSEPH | 1 | 53.1% | +58.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613006 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SKOKO III, JOHN JOSEPH | 31d overdue |
| 18702363 | TRIMETAZIDINE SALTS | CHENG, KAREN | — |
| 18038435 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | STONEBRAKER, ALYSSA RAE | — |
| 18004468 | DIOSMIN PREPARATION METHOD | LEE, HOI YAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1623 | 1 |
| 1642 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702363 | TRIMETAZIDINE SALTS | CHENG, KAREN | 1623 | §103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18574801 | PROCESS FOR PREPARING DIOSMIN AND FLAVONOID FRACTION | BERRY, LAYLA D | 1693 | §112 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18038435 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DP | Non-Final OA | — | Pending | May 23, 2023 |
| 18004468 | DIOSMIN PREPARATION METHOD | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17613006 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SKOKO III, JOHN JOSEPH | 1643 | §112DP | Final Rejection | 31d overdue | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial